{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-001398","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.196436+00:00","generated_at":"2026-06-07T03:11:28.475106+00:00","sec_items":["2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"AgeX draws $500K under secured convertible note with Juvenescence; due Feb 14, 2024","bullets":["Drew $500,000 on Jan 3, 2024 from Amended and Restated Secured Convertible Promissory Note.","Lender is Juvenescence Limited; repayment date set as February 14, 2024.","Other terms incorporated by reference from Nov 14, 2023 Form 10-Q.","Total outstanding under the note not disclosed in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-001398","json":"https://secwatch.observer/filing/0001493152-24-001398.json","markdown":"https://secwatch.observer/filing/0001493152-24-001398.md","text":"https://secwatch.observer/filing/0001493152-24-001398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224001398/0001493152-24-001398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224001398/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:11:28.475106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4ed45ecbf2997deb9db36e29831bdf4b454ff822","claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On January 3, 2024, AgeX drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited (“Juvenescence”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224001398/0001493152-24-001398-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$500,000"},{"label":"Counterparty","value":"Juvenescence Limited"},{"label":"Maturity","value":"February 14, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}